Issues in the Clinical Development of Investigational Agents Being Evaluated for the Post-surgical Adjuvant Treatment of High-Risk (Stage IIb and III) Melanoma

3/8/02


Click here to start


Table of Contents

Issues in the Clinical Development of Investigational Agents Being Evaluated for the Post-surgical Adjuvant Treatment of High-Risk (Stage IIb and III) Melanoma

Adjuvant Treatment for Malignant Melanoma Outline of Presentation

Adjuvant Treatment for Malignant Melanoma Outline of Presentation Invited Speakers

Adjuvant Treatment for Malignant Melanoma Regulatory considerations

Adjuvant Treatment for Malignant Melanoma Evolution in Regulatory Approach

Adjuvant Treatment for Malignant Melanoma Evolution in Regulatory Approach

Adjuvant Treatment for Malignant Melanoma

Adjuvant Treatment for Malignant Melanoma Survey Approach

Adjuvant Treatment for Malignant Melanoma Number of INDs for the Treatment of Melanoma

Adjuvant Treatment for Malignant Melanoma Number of Studies and Subjects Accrued by Phase of Study

Adjuvant Treatment for Malignant Melanoma Investigational Products

Adjuvant Treatment for Malignant Melanoma Investigational Products

Adjuvant Treatment for Malignant Melanoma Investigational Products

Adjuvant Treatment for Malignant Melanoma

Adjuvant Treatment for Malignant Melanoma Study ECOG 1684

Adjuvant Treatment for Malignant Melanoma Study ECOG 1684

Adjuvant Treatment for Malignant Melanoma Study ECOG 1684

Adjuvant Treatment for Malignant Melanoma K-M estimates of DFS ECOG 1684 (from the published report)

Adjuvant Treatment for Malignant Melanoma K-M estimates of OS ECOG 1684 (from the published report)

Adjuvant Treatment for Malignant Melanoma Labeled Indication

Adjuvant Treatment for Malignant Melanoma Study ECOG 1690

Adjuvant Treatment for Malignant Melanoma K-M estimates of DFS ECOG 1690 (from the published report)

Adjuvant Treatment for Malignant Melanoma K-M estimates of OS ECOG 1690 (from the published report)

Adjuvant Treatment for Malignant Melanoma K-M Estimates of 3-year RFS and OS Studies E 1684 and E1690 (high dose)

Adjuvant Treatment for Malignant Melanoma Interferon a 2b Adverse Events

Adjuvant Treatment for Malignant Melanoma Interferon a 2b Adverse Events

Adjuvant Treatment for Malignant Melanoma Use of INTRON-A in high risk melanoma Estimates for 2001

Adjuvant Treatment for Malignant Melanoma

Adjuvant Treatment for Malignant Melanoma Criteria for Inclusion

Adjuvant Treatment for Malignant Melanoma Search Methodology

Adjuvant Treatment for Malignant Melanoma Analytic Approach

Adjuvant Treatment for Malignant Melanoma INTRON-A High Dose

Adjuvant Treatment for Malignant Melanoma K-M estimates of DFS and OS ECOG 1694 (from the published report)

Adjuvant Treatment for Malignant Melanoma INTRON-A Low Dose

Adjuvant Treatment for Malignant Melanoma Rusciani et al. 1997 (from the published report)

Adjuvant Treatment for Malignant Melanoma K-M estimate of DFS and OS Scottish Melanoma Group (from the published report)

Adjuvant Treatment for Malignant Melanoma ROFERON-A High Dose and Low Dose

Adjuvant Treatment for Malignant Melanoma K-M estimate of DFS and OS NCCTG 83-7052 (from the published report)

Adjuvant Treatment for Malignant Melanoma K-M estimate of DFS WHO CT 16 (from the published report)

Adjuvant Treatment for Malignant Melanoma K-M estimate of DFS M 23031 (from the published report)

Adjuvant Treatment for Malignant Melanoma K-M estimate of DFS Austrian Melanoma Cooperative Group (from the published report)

PPT Slide

Adjuvant Treatment for Malignant Melanoma Odds Ratio for Survival

Adjuvant Treatment for Malignant Melanoma Wheatley et. al. Meta-Analysis

Adjuvant Treatment for Malignant Melanoma Overview by FDA and Wheatley

Adjuvant Treatment for Malignant Melanoma Overview

Adjuvant Treatment for Malignant Melanoma Summary

Adjuvant Treatment for Malignant Melanoma Effect Size Adjuvant Treatment Relative Reduction in the Odds of Recurrence and Death

PPT Slide

Adjuvant Treatment for Malignant Melanoma K-M estimates of DFS ECOG 1694 (from the published report)

Adjuvant Treatment for Malignant Melanoma K-M estimates of OS ECOG 1694 (from the published report)

Adjuvant Treatment for Malignant Melanoma K-M estimate of DFS Scottish Melanoma Group (from the published report)

Adjuvant Treatment for Malignant Melanoma K-M estimate of OS Scottish Melanoma Group (from the published report)

Adjuvant Treatment for Malignant Melanoma K-M estimate of DFS WHO CT 16 (from the published report)

Adjuvant Treatment for Malignant Melanoma K-M estimate of OS WHO CT 16 (from the published report)

Adjuvant Treatment for Malignant Melanoma K-M estimate of DFS M 23031 (from the published report)

Adjuvant Treatment for Malignant Melanoma K-M estimate of OS M 23031 (from the published report)

Adjuvant Treatment for Malignant Melanoma K-M estimate of DFS NCCTG 83-7052 (from the published report)

Adjuvant Treatment for Malignant Melanoma K-M estimate of OS NCCTG 83-7052 (from the published report)

Adjuvant Treatment for Malignant Melanoma K-M estimate of DFS M 23031 (from the published report)

Adjuvant Treatment for Malignant Melanoma Colon Cancer 5-FU levamisole

Adjuvant Treatment for Malignant Melanoma Colon Cancer 5-FU levamisole

Adjuvant Treatment for Malignant Melanoma Colon Cancer 5-FU levamisole

Adjuvant Treatment for Malignant Melanoma Colon Cancer 5-FU levamisole

Adjuvant Treatment for Malignant Melanoma Colon Cancer 5-FU levamisole

Adjuvant Treatment for Malignant Melanoma Breast Cancer Taxol

Adjuvant Treatment for Malignant Melanoma Breast Cancer Tamoxifen

Adjuvant Treatment for Malignant Melanoma K-M estimates of DFS ECOG 1684 (from the published report)

Adjuvant Treatment for Malignant Melanoma K-M estimates of OS ECOG 1684 (from the published report)

Adjuvant Treatment for Malignant Melanoma K-M estimates of DFS ECOG 1690 (from the published report)

Adjuvant Treatment for Malignant Melanoma K-M estimates of OS ECOG 1690 (from the published report)

PPT Slide

Adjuvant Treatment for Malignant Melanoma INTRON-A High Dose Results

Adjuvant Treatment for Malignant Melanoma INTRON-A Low Dose Results

Adjuvant Treatment for Malignant Melanoma ROFERON-A High Dose and Low Dose Results

Adjuvant Treatment for Malignant Melanoma Odds Ratio for Survival

Adjuvant Treatment for Malignant Melanoma Overview by FDA and Wheatley

Adjuvant Treatment for Malignant Melanoma Odds Ratio for Relapse

Author: cardinali